Can adding lenvatinib to standard care outsmart a tough brain cancer?

NCT ID NCT07754734

Not yet recruiting Disease control Sponsor: Dongguan People's Hospital Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This phase II trial is asking whether adding the drug lenvatinib to the standard STUPP regimen (temozolomide plus radiation) can improve outcomes for people newly diagnosed with a type of brain cancer called glioblastoma that has a specific genetic marker (MGMT promoter methylation). About 138 adults aged 18-75 will be randomly assigned to receive either the standard regimen alone or the standard regimen plus lenvatinib. The study will track how long participants live without the cancer progressing, overall survival, and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenvatinib combined with temozolomide and radiotherapy (the STUPP regimen)
What this could lead to: If adding lenvatinib to the standard STUPP regimen slows tumor growth, it could offer a new first-line treatment option for a subset of glioblastoma patients.
What could go wrong: This is an early-phase trial, so the benefit is unproven. Lenvatinib may add side effects without improving survival, and results may not apply to all glioblastoma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA (GBM) GLIOMA MGMT-METHYLATED GLIOBLASTOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.